The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Forecasted Market Size Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Compare Between 2026 And 2030?
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market size has experienced significant expansion in recent years. Projections indicate it will grow from $2.19 billion in 2025 to $2.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.9%. This historical growth was driven by factors such as increasing screening of sexually active populations, the expansion of laboratory-based testing infrastructure, the adoption of NAAT and PCR technologies, rising awareness of co-infection risks, and the proliferation of diagnostic laboratories.
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market size is projected to experience substantial growth over the next few years, reaching $3.47 billion by 2030 with a compound annual growth rate (CAGR) of 9.3%. This projected expansion can be attributed to several factors during the forecast period, including increasing investments in decentralized testing, a rise in the adoption of home-based diagnostics, the broadening of automated laboratory platforms, an escalating focus on early STI detection, and a growing demand for integrated CT/NG testing solutions. Major trends anticipated within the forecast period encompass the increasing adoption of multiplex STI testing panels, a rising demand for rapid point-of-care testing, the expanding use of self-testing kits, the development of high-sensitivity molecular assays, and enhanced integration of laboratory automation.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp
What Market Drivers Are Helping Shape The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Expansion?
The rising incidence of sexually transmitted infections (STIs) is anticipated to fuel the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market. These STIs are illnesses resulting from bacterial, viral, or parasitic infections transferable via sexual contact. Elevated STI rates stem from inadequate comprehensive sex education, heightened sexual activity, associated stigma, and accessibility barriers. Chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing facilitates the detection and management of STIs through early diagnosis, effective treatment, and transmission prevention. For example, data from October 2025 by the Minority HIV/AIDS Fund (MHAF), a US-based government agency, revealed that in 2023, an estimated 39.9 million people globally were living with HIV, including 38.6 million adults and 1.4 million children, an increase from prior years. Consequently, the growing prevalence of sexually transmitted infections is a key factor driving the expansion of the CTNG testing market.
How Are Different Segment Groups Identified Within The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market covered in this report is segmented –
1) By Test Type: Laboratory, Point Of Care Testing
2) By Product: Assays And Kits, Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
4) By End User: Diagnostic Laboratories, Hospitals And Clinics, Other End Users
Subsegments:
1) By Laboratory: Nucleic Acid Amplification Tests (NAAT), Polymerase Chain Reaction (PCR) Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Culture Tests, Direct Fluorescent Antibody (DFA) Tests
2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT), Lateral Flow Assays, Immunochromatographic Tests, Self-Testing Kits, Loop-Mediated Isothermal Amplification (LAMP), Microfluidics-Based Tests
What Trends Are Affecting The Growth Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Leading companies within the chlamydia market are concentrating on developing innovative solutions, such as the growth of Point-of-Care Molecular Diagnostics, to facilitate quicker, more precise detection on-site and enhance prompt treatment outcomes. This expansion of point-of-care molecular diagnostics signifies a wider adoption of rapid, on-location molecular assays that enable instant identification of infections like chlamydia, removing the dependency on central laboratory facilities. For instance, in January 2025, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, obtained FDA 510(k) clearance and a CLIA waiver for its cobas® liat molecular tests, which are specifically designed for diagnosing sexually transmitted infections (STIs) directly at the point of care. These particular tests feature multiplex assay panels capable of identifying and differentiating multiple STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient specimen, with results delivered within 20 minutes or less.
Which Companies Form The Competitive Landscape Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Major companies operating in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc, PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc, Meridian Bioscience Inc, Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd, Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd, NG Biotech
Access The Complete Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Report:
Which Region Has The Strongest Presence In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2025. The regions covered in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=14667&type=smp
Browse Through More Reports Similar to the Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market 2026, By The Business Research Company
Chlamydia Infection Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report
Chlamydia Infection Diagnostics And Therapeutics Global Market Report 2026
Sexually Transmitted Infections Stis Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model